Tempus AI (TEM) said Tuesday it is collaborating with Verastem (VSTM) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.
Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.
The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.